Villemagne, Victor L.
Doré, Vincent
Burnham, Samantha C.
Masters, Colin L.
Rowe, Christopher C.
Article History
First Online: 16 February 2018
Change Date: 7 June 2018
Change Type: Corrigendum
Change Details: In Figure 1 of this article as originally published, the chemical structure at bottom right was incorrectly labelled 18F-PM-PBB3. The text label has been corrected to 18F-PBB3 in the PDF and HTML versions of the article. As of this date, the structure of PM-PBB3 (also known as APN-1607) has not yet been published.
Competing interests
: V.L.V. declares that he has received consultancy fees from AbbVie, Hoffmann-La Roche, Lundbeck, Novartis and Shanghai Green Valley Pharmaceutical as well as honoraria for speaking from AbbVie, AstraZeneca, Avid Radiopharmaceuticals, GE Healthcare, Hoffmann-La Roche and Piramal Imaging. C.L.M. declares that he owns stock in or is a company director of Prana Biotechnology. C.C.R. declares that he has received consultancy fees from AstraZeneca, Avid Radiopharmaceuticals, Biogen, GE Healthcare and Piramal Imaging as well as honoraria for speaking from AbbVie, AstraZeneca, Avid Radiopharmaceuticals, GE Healthcare, Hoffmann-La Roche and Piramal Imaging and grants or research support from AstraZeneca, Avid Radiopharmaceuticals, Biogen, GE Healthcare and Piramal Imaging. V.D. and S.C.B. declare no competing interests.